Армоцибарт

Prop. INN (наименование, предложенное ВОЗ)

immunoglobulin G4-kappa, anti-[Homo sapiens TFPI (tissue factor pathway inhibitor, extrinsic pathway inhibitor, EPI, lipoprotein-associated coagulation inhibitor, LACI)];
H-gamma4 heavy chain (1-448) [VH Musmus/Homsap (Mus musculus IGHV1-81*01 (85.7%) -(IGHD) -IGHJ3*01 (83.3%) A128>S (121)/Homo sapiens IGHV1-18*01 (77.6%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, G4v5 h P10 (CH1 (122-219), hinge 1-12 S10>P (229) (220-231), CH2 L92 (310) (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-219')-disulfide with L-kappa light chain (1'-219') [V-KAPPA Musmus/Homsap (Mus musculus IGKV1-135*01 (86.0%) -IGKJ2*03 (81.8%) S120>Q (105') , L124>V (109')/Homo sapiens IGKV2-29*02 (84.0%) -IGKJ1*01 (100%), CDR-IMGT [11.3.9] (27'-37'.55'-57'.94'-102')) (1'-112') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (158'), V101 (196')) (113'-219')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

Поделиться этой страницей